In a murine melanoma tumor model, a treatment with the CCR4 antagonist in both prophylactic and therapeutic settings [313] is more efficient than cyclophosphamide to elicit Ag-specific CD8+ T cells and partly inhibit tumor growth [314]. This evidence concerns the gene CD8A and neoplasm.